Sawyer & Company Inc Purchases New Stake in AbbVie Inc. $ABBV

Key Points

• Sawyer & Company acquired 10,234 AbbVie shares during the third quarter, valued at approximately $2.68 million. Institutional investors collectively own 70.23% of the company.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $278.07; several firms recently raised their targets to around $300.
• AbbVie reported quarterly revenue of $16.99 billion and adjusted earnings of $3.65 per share, while declaring a quarterly dividend of $1.73, equivalent to a 2.4% yield.

Sawyer & Company Inc acquired a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,234 shares of the company's stock, valued at approximately $2,677,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Lifelong Wealth Advisors Inc. grew its holdings in AbbVie by 2.1% in the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company's stock valued at $459,000 after buying an additional 36 shares in the last quarter. James T. Borello RIA boosted its holdings in AbbVie by 3.5% in the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company's stock valued at $312,000 after purchasing an additional 40 shares during the last quarter. ACT Advisors LLC. boosted its holdings in AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after purchasing an additional 41 shares during the last quarter. Willner & Heller LLC grew its stake in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after buying an additional 43 shares during the period. Finally, B.O.S.S. Retirement Advisors LLC grew its stake in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after buying an additional 43 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ABBV shares. Citigroup raised their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. upped their price objective on AbbVie from $285.00 to $300.00 and gave the company an "overweight" rating in a report on Thursday, October 8th. BMO Capital Markets increased their price objective on AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Piper Sandler increased their price objective on AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. Finally, Wolfe Research raised AbbVie from a "peer perform" rating to an "outperform" rating and raised their target price for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $278.07.

AbbVie Price Performance

NYSE ABBV opened at $284.63 on Thursday. The firm's 50-day moving average is $264.93 and its two-hundred day moving average is $240.92. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $291.40. The stock has a market capitalization of $502.89 billion, a P/E ratio of 80.41, a PEG ratio of 1.32 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the firm posted $2.97 earnings per share. AbbVie's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts anticipate that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio is currently 195.48%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial
• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach
• Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie
• Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment.
• Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.